Home > Resources > Company Profiles > Merck & Company, Incorporated

Merck & Company, Incorporated (MRK)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Richard T. Clark , CEO/President/Director/Chairman of the Board

www.merck.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.

Portfolio Articles

Merck's Latest Headache
The drug company, reeling from nine-figure settlements for Vioxx, Vytorin, and Zetia, agrees to stump up another $650 million in a new case.
Feb 07 2008
A Big Name in Generic Drugs
Mylan expands its reach in the fast-growing market for off-patent pharmaceuticals with a $6.7 billion deal.
May 14 2007
Merck's Wild Ride
An upbeat earnings forecast and a legal victory overshadow potentially crushing regulatory news on Merck's latest drug.

Apr 13 2007
Setback for Merck on F.D.A. Ruling
A government panel rejects Merck's Arcoxia drug, the latest version of its ill-fated Vioxx.

Apr 12 2007

See more news on this company

News Feeds

Drugmakers in the Dow fall with the overall market AP
Oct 06 2008
Pharmaceutical shares dip after bailout passes AP
Oct 03 2008
Merck ends obesity drug study and regulatory plan AP
Oct 02 2008
Florida sues Merck to recover money spent on Vioxx AP
Oct 01 2008
Drugmakers see mixed results for shares in Q3 AP
Sep 30 2008
Merck licenses osteoporosis drug candidate AP
Sep 25 2008
Merck to contract out some sales jobs _ after cuts AP
Sep 22 2008
Brazil to make AIDS drug after Merck talks fail AP
Sep 18 2008
U.S. Merck's Japan unit to slash sales branches Reuters
Sep 17 2008
New Merck osteoporosis drug boosts bone density AP
Sep 16 2008

Portfolio Blogs

Easing the Pain for Some Vioxx Lawyers
Nov 14 2007

Press Releases

Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team Oct-02-2008, 09:00AM EDT
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity Oct-02-2008, 08:00AM EDT
Merck Serono Among the Winners in the German BioPharma Strategy Competition Oct-01-2008, 11:16AM EDT
Inotek Appoints Paul G. Howes as President and CEO Oct-01-2008, 10:00AM EDT
BIO-Europe 2008: World's Top Pharmaceutical Firms to Gather in Force Seeking Partnerships and Discovering New Ways to Enhance Deal Values Sep-30-2008, 09:53AM EDT

News From Around the Web

News

Drugmakers in the Dow fall with the overall market (Boston Globe)

Oct 06 2008
Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK) (24/7 Wall St.)

Oct 06 2008
Is It Time to Run and Hide? (Motley Fool)

Oct 06 2008
Merck Discontinues Development Of Investigational Medicine Taranabant For Obesity (Medical News Today)

Oct 06 2008
Merck stops development of obesity drug taranabant (Courier-Post Online, New Jersey)

Oct 05 2008
State sues Merck for deceptive marketing of Vioxx (BizJournals)

Oct 04 2008
Merck pulls plug on obesity drug (BizJournals)

Oct 04 2008
Pharmaceutical shares dip after bailout passes (Boston Globe)

Oct 03 2008

Blogs

Election bets: Advisors vote on McCain and Obama stocks (Blogging Stocks)

Oct 03 2008
Merck pull taranabant (PharmaGossip)

Oct 02 2008

Employees

Number of Employees: 59,800

Revenue per Employee: $399,983

Top Executives

Wendy L. Yarno, Other Executive Officer

Stefan Oschmann, President, Geographical

J. Chris Scalet, Chief Information Officer/Executive VP, Divisional

Dr.Mirian M. Graddick-Weir, Executive VP, Divisional

Bruce N. Kuhlik, Executive VP/General Counsel

Kenneth C. Frazier, Executive VP/President, Divisional

Margaret G. McGlynn, Divisional President

Willie A. Deese, Executive VP/President, Divisional

Peter N. Kellogg, Executive VP/CFO

Adele D. Ambrose, Vice President/Other Executive Officer

Mark E. Mcdonough, Treasurer/Vice President

Adam H. Schechter, President, Divisional

Celia A. Colbert, Senior VP/Secretary

David W. Anstice, Executive VP, Divisional

Peter S. Kim, Divisional President/Executive VP

Steven Kelmar, Vice President, Divisional

John Canan, Controller/Senior VP

Board of Directors

Leslie A. Brun, Director

Thomas Henry (Tom) Glocer, Director

Dr.William N. Kelley, M.D., Director

Dr. Samuel O. Thier, M.D., Director

Dr. Johnnetta B. Cole, Ph.D., Director

William B. Harrison, Jr., Director

Anne M. Tatlock, Director

Steven F. Goldstone, Director

Dr.Harry R. Jacobson, M.D., Director

Mark E. Mcdonough, Treasurer/Vice President

Peter C. Wendell, Director

Rochelle B. Lazarus, Director

Wendell P. Weeks, Director

Celia A. Colbert, Senior VP/Secretary

Dr.Thomas E. Shenk, Ph.D., Director

Financials

Quarterly

Annual

Income Statement	08/2008	02/2008	10/2007	07/2007
Sales	847 Mil.	1.05 Bil.	1.03 Bil.	1.05 Bil.
Gross Operating Profit	4.98 Bil.	5.2 Bil.	5.05 Bil.	5.06 Bil.
Operating Income before D & A (EBITDA)	2.04 Bil.	2.1 Bil.	1.65 Bil.	1.94 Bil.
Total Income Before Interest Expenses (EBIT)	4.52 Bil.	-3.06 Bil.	2.19 Bil.	2.37 Bil.
Total Net Income	3.3 Bil.	-1.63 Bil.	1.53 Bil.	1.68 Bil.
Basic EPS, Total	1.53	-0.75	0.7	0.77
Diluted EPS, Total	1.52	-0.75	0.7	0.77

BALANCE STATEMENT	08/2008	02/2008	10/2007	07/2007
Cash and Equivalents	6.29 Bil.	5.34 Bil.	5.21 Bil.	3.47 Bil.
Total Assets	17.05 Bil.	15.05 Bil.	14.16 Bil.	12.44 Bil.
Total Liabilities	9.8 Bil.	12.26 Bil.	10.51 Bil.	10.28 Bil.
Total Capitalization	23.49 Bil.	22.1 Bil.	24.6 Bil.	23.61 Bil.

Cash Flow	08/2008	02/2008	10/2007	07/2007
Net Cash From Continuing Operations	2.53 Bil.	7 Bil.	4.65 Bil.	1.63 Bil.
Net Cash From Investing Activities	1.9 Bil.	-2.81 Bil.	-1.96 Bil.	-1.89 Bil.
Net Cash From Financing Activities	-3.58 Bil.	-4.87 Bil.	-3.47 Bil.	-2.21 Bil.
Net Change in Cash & Cash Equivalents	953.3 Mil.	-578.6 Mil.	-706.4 Mil.	-2.45 Bil.

Income Statement	2008	2007	2006	2005
Sales	4.15 Bil.	3.73 Bil.	3.44 Bil.	3.51 Bil.
Gross Operating Profit	20.05 Bil.	18.9 Bil.	18.57 Bil.	19.43 Bil.
Operating Income before D & A (EBITDA)	7.61 Bil.	5.96 Bil.	7.57 Bil.	8.07 Bil.
Total Income Before Interest Expenses (EBIT)	3.88 Bil.	6.72 Bil.	7.87 Bil.	8.42 Bil.
Total Net Income	3.28 Bil.	4.43 Bil.	4.63 Bil.	5.81 Bil.
Basic EPS, Total	1.51	2.04	2.11	2.62
Diluted EPS, Total	1.49	2.03	2.1	2.61

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	5.34 Bil.	5.91 Bil.	9.59 Bil.	2.88 Bil.
Total Assets	15.05 Bil.	15.23 Bil.	21.05 Bil.	13.48 Bil.
Total Liabilities	12.26 Bil.	12.72 Bil.	13.3 Bil.	11.74 Bil.
Total Capitalization	22.1 Bil.	23.11 Bil.	23.04 Bil.	21.98 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	7 Bil.	6.77 Bil.	7.61 Bil.	8.8 Bil.
Net Cash From Investing Activities	-2.81 Bil.	-4.88 Bil.	2.27 Bil.	-1.64 Bil.
Net Cash From Financing Activities	-4.87 Bil.	-5.6 Bil.	-3.04 Bil.	-5.59 Bil.
Net Change in Cash & Cash Equivalents	-578.6 Mil.	-3.67 Bil.	6.71 Bil.	1.68 Bil.

Merck & Company, Incorporated (MRK)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request